“…Furthermore, studies of genetic polymorphisms have also been published in order to elucidate the genetic defects leading to asthma, such as single nucleotide polymorphisms (SNP) in the filaggrin gene (RS 11204981)(PAVLYK, 2016), haplotypes in the leukocyte antigen numbers of polymorphisms of pentanucleotides (HIRAI, 2018), CD14 (NIETO-FONTARIGO, 2018), TAP-1 (HLA-g) (RIBEYRE, 2018), ADRB2 (SENN, 2018), NOS2(HANG, 2003), cytokines TNF-α (MAKAMURE, 2016), IL-1 β (BIRBIAN, 2013), IL-13 (XU, 2017), and TLR4 (YAO, 2014).The immunological mechanisms studied were fundamental to the development of strategies for the treatment of asthmatic patients. Currently, there are therapies such as the use of corticosteroids, β2-AR agonists, and leukotriene modulators (DURHAM, 2017), and immunotherapies to desensitize patients to allergens, and in more severe cases, blockage of the main proinflammatory cytokines such as IL-5, IL-13, IL-4, or IL-17 is carried out (PELAIA, 2017; WALSH, 2017).…”